JPWO2007088971A1 - がん予後判定に利用できる遺伝子群 - Google Patents
がん予後判定に利用できる遺伝子群 Download PDFInfo
- Publication number
- JPWO2007088971A1 JPWO2007088971A1 JP2007556931A JP2007556931A JPWO2007088971A1 JP WO2007088971 A1 JPWO2007088971 A1 JP WO2007088971A1 JP 2007556931 A JP2007556931 A JP 2007556931A JP 2007556931 A JP2007556931 A JP 2007556931A JP WO2007088971 A1 JPWO2007088971 A1 JP WO2007088971A1
- Authority
- JP
- Japan
- Prior art keywords
- breast cancer
- expression level
- gene
- marker gene
- metastatic breast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 67
- 206010028980 Neoplasm Diseases 0.000 title description 18
- 201000011510 cancer Diseases 0.000 title description 17
- 238000004393 prognosis Methods 0.000 title description 2
- 230000014509 gene expression Effects 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 47
- 210000001519 tissue Anatomy 0.000 claims abstract description 37
- 210000004027 cell Anatomy 0.000 claims abstract description 35
- 206010055113 Breast cancer metastatic Diseases 0.000 claims abstract description 33
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 32
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 32
- 230000000683 nonmetastatic effect Effects 0.000 claims abstract description 17
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims abstract description 16
- 239000003550 marker Substances 0.000 claims description 38
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000006402 Ductal Carcinoma Diseases 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000033206 Early menarche Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000029691 metastatic malignant neoplasm in the lymph nodes Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
(2)マーカー遺伝子の発現レベルが、その遺伝子のmRNA量で表されることを特徴とする、前記(1)に記載の判定方法。
(3)マーカー遺伝子が、GenBank登録番号NM000903、NM006804、NM033547、CR611676、NM177967、NM152558、NM178167、NM003752、AK131568、CR592336、NM178507、NM002862、NM006913、NM005794、NM014164、NM000853および3番染色体178882962bpから178883181bpの塩基配列を有する遺伝子またはそのホモログからなる群のうちの、1または2以上より選択されることを特徴とする、前記(1)または(2)に記載の判定方法。
(4)ヒトの転移性乳癌組織(または細胞)と非転移性乳癌組織(または細胞)におけるマーカー遺伝子の発現レベルの差が、2倍以上または1/2以下である、前記(1)から(3)のいずれかに記載の判定方法。
Claims (4)
- ヒトの転移性乳癌組織(または細胞)と非転移性乳癌組織(または細胞)における、マーカー遺伝子の発現レベルの差を指標にすることを特徴とする、乳癌のリンパ節転移可能性の判定方法。
- マーカー遺伝子の発現レベルが、その遺伝子のmRNA量で表されることを特徴とする、請求項1に記載の判定方法。
- マーカー遺伝子が、GenBank登録番号NM000903、NM006804、NM033547、CR611676、NM177967、NM152558、NM178167、NM003752、AK131568、CR592336、NM178507、NM002862、NM006913、NM005794、NM014164、NM000853および3番染色体178882962bpから178883181bpの塩基配列を有する遺伝子またはそのホモログからなる群のうちの、1または2以上より選択されることを特徴とする、請求項1または2に記載の判定方法。
- ヒトの転移性乳癌組織(または細胞)と非転移性乳癌組織(または細胞)におけるマーカー遺伝子の発現レベルの差が、2倍以上または1/2以下である、請求項1から3のいずれかに記載の判定方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006027735 | 2006-02-03 | ||
JP2006027735 | 2006-02-03 | ||
PCT/JP2007/051800 WO2007088971A1 (ja) | 2006-02-03 | 2007-02-02 | がん予後判定に利用できる遺伝子群 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPWO2007088971A1 true JPWO2007088971A1 (ja) | 2009-06-25 |
Family
ID=38327539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007556931A Pending JPWO2007088971A1 (ja) | 2006-02-03 | 2007-02-02 | がん予後判定に利用できる遺伝子群 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090011423A1 (ja) |
EP (4) | EP2380978A3 (ja) |
JP (1) | JPWO2007088971A1 (ja) |
CA (1) | CA2641410A1 (ja) |
WO (1) | WO2007088971A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012515538A (ja) * | 2009-01-21 | 2012-07-12 | ユニヴァーシタ デグリ ステューディ ディ パドヴァ | 2つの遺伝子の発現の観察による乳癌患者の予後診断 |
JP5018918B2 (ja) * | 2010-03-17 | 2012-09-05 | パナソニック株式会社 | アンテナ装置およびそれを用いた携帯端末装置 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11178578A (ja) * | 1997-12-24 | 1999-07-06 | Otsuka Pharmaceut Co Ltd | ヒトrnf5遺伝子 |
AU2001247317A1 (en) * | 2000-03-13 | 2001-09-24 | Research Foundation For Mental Hygeine, Inc. | A lysosomal pepstatin-insensitive proteinase as a novel biomarker for detecting and diagnosing breast cancer |
AU2001273392A1 (en) * | 2000-07-11 | 2002-01-21 | Vanderbilt University | Method of detecting an increased susceptibility to breast cancer |
US20020107215A1 (en) * | 2000-08-01 | 2002-08-08 | Lifespan Biosciences, Inc. | Tissue-associated proteins and their uses |
US20030147866A1 (en) * | 2001-04-04 | 2003-08-07 | Nicolette Charles A. | Novel BGP compounds for therapy and diagnosis and methods for using same |
US20030108890A1 (en) * | 2001-05-30 | 2003-06-12 | Baranova Anna Vjacheslavovna | In silico screening for phenotype-associated expressed sequences |
JP2003043046A (ja) * | 2001-07-31 | 2003-02-13 | Chemo Sero Therapeut Res Inst | 乳癌判定用マーカー及び該マーカーを用いる乳癌の判定方法 |
US7781161B2 (en) * | 2002-03-07 | 2010-08-24 | The Johns Hopkins University School Of Medicine | Genomic screen for epigenetically silenced tumor suppressor genes |
JP2003284596A (ja) | 2002-03-29 | 2003-10-07 | Sumitomo Chem Co Ltd | 乳がん細胞の検出方法 |
JP2003284594A (ja) | 2002-03-29 | 2003-10-07 | Sumitomo Chem Co Ltd | 卵巣がん細胞の検出方法 |
US7473526B2 (en) * | 2002-03-29 | 2009-01-06 | Veridex, Llc | Breast cancer prognostic portfolio |
JP2004151003A (ja) * | 2002-10-31 | 2004-05-27 | Hiroko Nogi | Muc1およびケラチン19の検査方法 |
US20030224411A1 (en) * | 2003-03-13 | 2003-12-04 | Stanton Lawrence W. | Genes that are up- or down-regulated during differentiation of human embryonic stem cells |
US7306910B2 (en) * | 2003-04-24 | 2007-12-11 | Veridex, Llc | Breast cancer prognostics |
EP1670942A2 (en) * | 2003-09-04 | 2006-06-21 | InterGenetics, Inc. | Genetic analysis for stratification of breast cancer risk |
WO2005029067A2 (en) * | 2003-09-24 | 2005-03-31 | Oncotherapy Science, Inc. | Method of diagnosing breast cancer |
EP1756309A2 (en) * | 2004-06-03 | 2007-02-28 | Bayer HealthCare AG | Methods for predicting and monitoring response to cancer therapy |
-
2007
- 2007-02-02 EP EP11005113A patent/EP2380978A3/en not_active Withdrawn
- 2007-02-02 EP EP07707949A patent/EP1983046A4/en not_active Withdrawn
- 2007-02-02 WO PCT/JP2007/051800 patent/WO2007088971A1/ja active Application Filing
- 2007-02-02 CA CA002641410A patent/CA2641410A1/en not_active Abandoned
- 2007-02-02 EP EP11005112A patent/EP2380977A3/en not_active Withdrawn
- 2007-02-02 JP JP2007556931A patent/JPWO2007088971A1/ja active Pending
- 2007-02-02 EP EP10014665A patent/EP2295561A3/en not_active Withdrawn
-
2008
- 2008-07-31 US US12/183,610 patent/US20090011423A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090011423A1 (en) | 2009-01-08 |
EP2380977A3 (en) | 2012-02-15 |
EP2380978A2 (en) | 2011-10-26 |
EP1983046A1 (en) | 2008-10-22 |
EP2295561A2 (en) | 2011-03-16 |
EP2380977A2 (en) | 2011-10-26 |
EP2295561A3 (en) | 2011-06-29 |
CA2641410A1 (en) | 2007-08-09 |
EP1983046A4 (en) | 2009-03-25 |
WO2007088971A1 (ja) | 2007-08-09 |
EP2380978A3 (en) | 2012-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107326066B (zh) | 用于膀胱癌检测的尿标记物 | |
EP3303618B1 (en) | Methods of prostate cancer prognosis | |
US20140349856A1 (en) | Neuroendocrine Tumors | |
US20100075323A1 (en) | Molecular markers for lung and colorectal carcinomas | |
EP1608964A1 (en) | Expression profiling of tumours | |
BRPI0707642A2 (pt) | taxas de expressço de gene de urina para detecÇço de cÂncer | |
CN106676191B (zh) | 一种用于结肠腺癌的分子标志物 | |
US20110183862A1 (en) | Molecular signature of liver tumor grade and use to evaluate prognosis and therapeutic regimen | |
US20160222461A1 (en) | Methods and kits for diagnosing the prognosis of cancer patients | |
CN111269985B (zh) | hsa_circRNA6448-14在食管鳞癌诊断以及预后预测中的应用 | |
KR20180007291A (ko) | 암 리스크를 검출하는 방법 | |
CN108949969B (zh) | 长链非编码rna在结直肠癌中的应用 | |
KR101847815B1 (ko) | 삼중음성유방암의 아형 분류 방법 | |
JP6608424B2 (ja) | 前癌性結腸直腸ポリープおよび結腸直腸癌を特定するための方法およびキット | |
US20120034235A1 (en) | Marker for Liver-Cancer Diagnosis and Recurrence and Survival Prediction, a Kit Comprising the Same, and Prognosis Prediction in Liver-Cancer Patients Using the Marker | |
JPWO2007088971A1 (ja) | がん予後判定に利用できる遺伝子群 | |
CN109439760B (zh) | Arrdc2在评估口腔鳞癌发展进程中的应用 | |
EP1682679B1 (en) | Molecular marker | |
WO2022196750A1 (ja) | 子宮体がんのリンパ節転移能の評価方法のためのコンパニオンマーカー | |
US20220064235A1 (en) | Urine Markers and Methods for Detection of Bladder Cancer and Treatment Thereof | |
JP2006166789A (ja) | 癌の新規診断方法 | |
JP2007061047A (ja) | 乳癌細胞の検出方法 | |
CN116479123A (zh) | m7G相关lncRNA作为生物标志物在肝癌预后或治疗反应预测中的应用及产品和系统 | |
AU2007345912B2 (en) | Method of detecting mammary cancer cells | |
JP5861048B1 (ja) | 遺伝子発現解析による大腸癌の検出 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100304 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100604 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120612 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120813 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120904 |